Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Caspofungin.

Stanley C Deresinski1, David A Stevens

  • 1Department of Medicine, Santa Clara Valley Medical Center, San Jose, CA, 95128, USA.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|May 27, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drug Interactions for Inhibition or Killing of <i>Coccidioides</i> Species.

Journal of fungi (Basel, Switzerland)·2026
Same author

Cultryx: Precision Diagnostic Stewardship for Blood Cultures Using Machine Learning.

medRxiv : the preprint server for health sciences·2026
Same author

Antifungal activity of the antimicrobial peptide RP557 against priority fungal pathogens.

Microbiology (Reading, England)·2026
Same author

Machine Learning-Based Prediction of Antimicrobial Susceptibility: A Step Towards Precision Antimicrobial Stewardship.

AMIA ... Annual Symposium proceedings. AMIA Symposium·2026
Same author

A Multi-Phase Analysis of Blood Culture Stewardship: Machine Learning Prediction, Expert Recommendation Assessment, and LLM Automation.

AMIA ... Annual Symposium proceedings. AMIA Symposium·2026
Same author

Killing of <i>Coccidioides</i> by drugs.

Microbiology (Reading, England)·2026
Same journal

Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Low Post-Treatment Recurrence After a Shortened All-oral Regimen for Pulmonary Rifampicin- or Multidrug-Resistant Tuberculosis in Individuals without Prior Second-Line Drug Exposure in Kazakhstan.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Sepsis Diagnostic Excellence and its Association with Mortality in Adults with Potential Infection.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

10-Year Trends in Attributable and Contributable Mortality of Culture-Positive Invasive Aspergillosis in Patients with Hematologic Malignancies: Have We Reached the "Ceiling Efficacy Effect" of Modern Antifungals?

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Virologic Outcomes After LA ART Initiation with and without Viremia in Two Large U.S. Clinic Cohorts.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Andes Virus Exposure and Nosocomial Transmission Events to Healthcare Personnel: A Systematic Review.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
See all related articles

Caspofungin is a novel antifungal drug effective against various fungal infections like candidiasis and aspergillosis. It shows good safety and potential for empirical therapy, often without antagonism when combined with other antifungals.

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Caspofungin is the first approved inhibitor of fungal beta-1,3 glucan synthesis.
  • It targets critical pathways in fungal cell wall formation.

Purpose of the Study:

  • To review the efficacy and safety of caspofungin.
  • To explore its potential in treating various fungal infections and its use in combination therapy.

Main Methods:

  • Review of clinical trial data and in vitro/animal studies.
  • Analysis of efficacy against Candida, Aspergillus, and other fungi.
  • Assessment of safety profile and drug interactions.

Main Results:

  • Caspofungin demonstrates effectiveness in treating mucosal and invasive candidiasis and invasive aspergillosis.

Related Experiment Videos

  • It shows activity against other fungi and in Pneumocystis carinii infections.
  • No antagonism observed when combined with azole or polyene antifungals; excellent safety profile.

    • Conclusions:

    • Caspofungin is a valuable addition to antifungal treatments.
    • It holds promise for empirical therapy of invasive fungal infections.
    • Further clinical data on combination therapy is anticipated.